Physician profile

Robert Daniel Moore

Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) · Alpharetta, GA

NPI 1518093673

$1,174.56

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$417.67

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Olympus America INC. $379.89 2019-2023
Baxter Healthcare $261.09 2019-2024 Floseal
Astellas Pharma US INC $171.79 2019-2021
Stryker Corporation $154.35 2022
Caldera Medical, INC $139.60 2023 Desara
Axonics, INC. $39.57 2022
Coloplast Corp $15.25 2019
Boston Scientific Corporation $13.02 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Daniel Moore

$1,174.56

in general payments reported 2019-2025

Years
2019-2024
Top company
Olympus America INC.

https://glasscript.com/doctor/158686/robert-daniel-moore

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.